Ponappan Benny, Elkandow Ali, Abdelrahim Mohammed Gafar, Rehman Mujeeb Ur, Shaban Eman, Shaban Ahmed, Shaban Amira, Abosamak Mohammed F, Zaki Hany A
Emergency Department, Hamad Medical Corporation, Doha, QAT.
Cardiology Department, Al Jufairi Diagnosis and Treatment, Doha, QAT.
Cureus. 2025 Jun 16;17(6):e86157. doi: 10.7759/cureus.86157. eCollection 2025 Jun.
Postoperative pain (POP) is one of the leading clinical challenges of patients undergoing major surgeries, including abdominal surgeries. Opioid analgesics are considered the gold standard for POP. However, their use is associated with a high incidence of adverse events, including nausea and vomiting, which has prompted clinicians to look for alternative regimens that are not opioid-based. This review aims to provide an overview of the existing evidence regarding the effectiveness of non-opioid analgesics (NOAs) in the management of POP in patients who have undergone major abdominal surgeries. A comprehensive search was conducted on four databases: Google Scholar, PubMed, CENTRAL, and Science Direct. The studies that met the inclusion criteria were then included in the review. The reported outcomes were pooled using the Review Manager software (RevMan 5.4, The Cochrane Collaboration, London, UK). The literature search identified 657 articles, among which 18 were included in the review according to the inclusion criteria. Our study found that the mean postoperative opioid consumption was significantly lower among individuals treated with non-opioid analgesics than with opioid analgesics SMD -1.88; 95% CI (-2.40, -1.36); p < 0.0001). Further analysis showed that the mean opioid consumption was also lower in those who received NSAIDs and other atypical analgesics (SMD -2.24; 95% CI (-2.94, -1.55); p < 0.00001) and (SMD -1.18; 95% CI (-2.18, -0.17); p = 0.02), respectively. However, in those who received paracetamol, the mean opioid consumption was comparable to that of controls (SMD -1.09; 95% CI (-2.21, 0.03); p = 0.06). Secondly, our study found that the incidence of opioid-related nausea was reduced in patients who received NOA than in controls (OR 0.38; 95% CI (0.22, 0.66); p = 0.0005). However, the incidence of vomiting was equivalent across both groups (OR 0.64; 95% CI (0.39, 1.04); p = 0.07). This study found that NOAs are good adjuvants in pain management in patients undergoing major abdominal surgery. They aid in reducing the dosage of opioids required for adequate analgesia and thus also reduce the incidence of some of the related adverse events.
术后疼痛(POP)是包括腹部手术在内的大型手术患者面临的主要临床挑战之一。阿片类镇痛药被认为是术后疼痛治疗的金标准。然而,其使用与包括恶心和呕吐在内的高不良事件发生率相关,这促使临床医生寻找非阿片类的替代方案。本综述旨在概述关于非阿片类镇痛药(NOAs)在接受大型腹部手术患者的术后疼痛管理中有效性的现有证据。我们在四个数据库进行了全面检索:谷歌学术、PubMed、CENTRAL和科学Direct。然后将符合纳入标准的研究纳入综述。使用Review Manager软件(RevMan 5.4,英国伦敦科克伦协作网)汇总报告的结果。文献检索共识别出657篇文章,其中18篇根据纳入标准纳入本综述。我们的研究发现,接受非阿片类镇痛药治疗的个体术后阿片类药物平均消耗量显著低于接受阿片类镇痛药治疗的个体(标准化均数差 -1.88;95%置信区间(-2.40,-1.36);p<0.0001)。进一步分析表明,接受非甾体抗炎药和其他非典型镇痛药的个体阿片类药物平均消耗量也较低(标准化均数差 -2.24;95%置信区间(-2.94,-1.55);p<0.00001)和(标准化均数差 -1.18;95%置信区间(-2.18,-0.17);p = 0.02)。然而,接受对乙酰氨基酚治疗的个体阿片类药物平均消耗量与对照组相当(标准化均数差 -1.09;95%置信区间(-2.21,0.03);p = 0.06)。其次,我们的研究发现,接受非阿片类镇痛药治疗的患者阿片类药物相关恶心的发生率低于对照组(比值比 0.38;95%置信区间(0.22,0.66);p = 0.0005)。然而,两组呕吐发生率相当(比值比 0.64;95%置信区间(0.39,1.04);p = 0.07)。本研究发现,非阿片类镇痛药是大型腹部手术患者疼痛管理的良好辅助药物。它们有助于减少充分镇痛所需的阿片类药物剂量,从而也降低了一些相关不良事件的发生率。